Last updated on September 2018

A Study of ELIGARD in Hormone-dependent Prostate Cancer Patients


Brief description of study

The objective of this study is to evaluate the safety, efficacy, and impact on quality of life (QoL) of ELIGARD in hormone-dependent prostate cancer patients in Asia.

Clinical Study Identifier: NCT03035032

Contact Investigators or Research Sites near you

Start Over

Astellas Pharma Inc.

Site HK01002
Hong Kong, Hong Kong

Astellas Pharma Inc.

Site HK01001
Hong Kong, Hong Kong